SureTrader Nadex Advertisement
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/24/2017 4:29:29 AM - Followers: 4 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXBDF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#403   Oxford Biomedica lauds “encouraging” trial results from a georgejjl 02/24/17 04:29:29 AM
#402   Conclusions: Both CPM and TroVax induced highly beneficial marcusl2 02/23/17 03:33:31 PM
#401   HTTP://abstracts.asco.org/194/AbstView_194_178575.html MVA-5T4 immunotherapy marcusl2 02/23/17 08:55:29 AM
#400   Very interesting georgejjl 02/15/17 10:57:49 PM
#399   Oxford Biomedica Set To Flirt With Venture Financing georgejjl 02/13/17 08:03:13 PM
#398   Such high ambitions draw an obvious comparison between marcusl2 02/13/17 05:01:50 PM
#397   3 weeks marcusl2 01/31/17 09:18:42 AM
#396   How do you understand that patent George as marcusl2 01/29/17 03:32:37 PM
#395   5T4 and Cellectis patent georgejjl 01/29/17 10:49:06 AM
#394   Oxford BioMedica and Immune Design's LV305 trial in progress georgejjl 01/28/17 12:28:25 PM
#393   Oxford BioMedica and Orchard Therapeutics georgejjl 01/28/17 12:15:35 PM
#392   Medimmune's MEDI0641, a novel antibody-drug conjugate targeted to 5T4 georgejjl 01/28/17 12:02:47 PM
#391   Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T georgejjl 01/28/17 11:39:03 AM
#390   New Novartis trial about the start for the georgejjl 01/28/17 11:27:04 AM
#389   CTL019 therapy for multiple myeloma from Oxford georgejjl 01/28/17 11:14:45 AM
#388   CART therapy in the news georgejjl 01/28/17 10:47:44 AM
#387   we forecast at least $1bn WW peak sales marcusl2 01/27/17 05:21:52 PM
#386   CTL019 on its pipeline of possible blockbusters, underscoring marcusl2 01/26/17 07:55:39 AM
#385   Twitter in June ; marcusl2 01/23/17 04:59:34 PM
#384   Novartis CAR T therapy and Oxford BioMedica full georgejjl 01/21/17 07:58:12 PM
#383   https://www.unil.ch/ib/home/news.html?showActu=1478767577494136&showFrom=1&actun marcusl2 01/21/17 04:52:45 PM
#382   CART 5T4 georgejjl 01/21/17 03:28:38 PM
#381   Jefferies & Co Indicates Potential 92.77% Increase In marcusl2 01/05/17 07:51:30 AM
#380   Trovax HTTP://immunosym.org/program/poster-sessions Poster Session A: Humora marcusl2 12/30/16 04:33:02 AM
#379   Oxford Biomedica (OXBDF) Given “Buy” Rating at Roth Capital georgejjl 12/09/16 06:54:19 PM
#378   Excellent results, marcusl2 12/04/16 05:24:50 AM
#377   Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics marcusl2 11/29/16 08:59:47 AM
#376   Latest results demonstrate that those patients whose immune marcusl2 11/27/16 09:08:31 AM
#375   Seeking Alpha georgejjl 11/21/16 07:55:27 PM
#374   https://www.youtube.com/watch?v=Yg9DtJKpbsM&app=desktop Signing more deals late marcusl2 11/15/16 04:52:35 AM
#373   Novartis` marcusl2 11/07/16 09:36:05 AM
#372   This will rocket if news on Trovax, CTL019 marcusl2 11/04/16 03:22:39 PM
#371   5T4 antibody drug conjugate georgejjl 11/04/16 01:12:05 AM
#370   CART 5T4 georgejjl 11/04/16 01:07:36 AM
#369   HTTP://www.essentialkids.com.au/health/allergies-illness/girl6-battling-cancer-f marcusl2 11/01/16 05:15:11 AM
#368   CAR-T 5T4 cell therapy: OXB-302 for targeting solid cancer georgejjl 10/24/16 07:29:23 AM
#367   Broker Forecast - Jefferies International issues a broker marcusl2 10/21/16 09:33:05 AM
#366   George, this is interesting; 5T4 oncofoetal antigen: an marcusl2 10/19/16 10:53:37 AM
#365   The patents are baffling to me! marcusl2 10/16/16 08:12:24 AM
#364   Is this a complication or an opportunity? georgejjl 10/16/16 07:56:28 AM
#363   Phase II/III trials look likely with survival end-points marcusl2 10/13/16 04:29:59 AM
#362   Case Studies marcusl2 10/13/16 04:29:15 AM
#361   Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) marcusl2 10/10/16 04:43:11 AM
#360   That would be an added bonus George. Let`s marcusl2 10/03/16 10:40:48 AM
#359   I believe that Oxford BioMedica is working on georgejjl 10/01/16 12:42:33 PM
#358   I didn`t see any mention of 5T4 marcusl2 10/01/16 09:52:58 AM
#357   Novartis and Oxford BioMedica's CART therapy for various georgejjl 09/30/16 08:56:02 AM
#356   Just imagine what the new improved version of georgejjl 09/26/16 06:21:28 AM
#355   Pfizer is still interested in 5T4. georgejjl 09/26/16 05:31:47 AM
#354   http://uk.advfn.com/stock-market/london/oxford-biomedica-OXB/share-news/Oxford-B marcusl2 09/19/16 03:16:24 PM
PostSubject